10014-CBMS-2 CONCURRENT TARGETING OF MDM4 AND MDM2 USING CEP-1347 AS AN EFFECTIVE THERAPEUTIC STRATEGY FOR P53 WILD-TYPE MALIGNANT BRAIN TUMORS

Yuta Mitobe, Yukihiko Sonoda, Chifumi Kitanaka · 2023

Read 10014-CBMS-2 CONCURRENT TARGETING OF MDM4 AND MDM2 USING CEP-1347 AS AN EFFECTIVE THERAPEUTIC STRATEGY FOR P53 WILD-TYPE MALIGNANT BRAIN TUMORS by Yuta Mitobe, Yukihiko Sonoda, Chifumi Kitanaka (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710601.txt.

Description

Yuta Mitobe, Yukihiko Sonoda, and Chifumi Kitanaka test a two-front attack on malignant brain tumors that keep a working p53 gene. The protein p53 can force cancer cells to die, but two partner proteins, MDM2 and MDM4, hold it down. Drugs that free p53 by blocking one partner are a hot strategy.

A compound called CEP-1347 lowered MDM4 as hoped, yet it also raised MDM2, which blunted the gain. Cutting MDM2 by gene tools made things worse in a subtle way. Pairing the compound with a drug that blocks MDM2's grip on p53, while sparing its other jobs, worked best. The pair cut MDM4, woke p53, and slowed growth.

Catalog record

CREATORYuta Mitobe, Yukihiko Sonoda, Chifumi Kitanaka
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710601

Browse the full library · About the Tower of Babel